TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology
Launched by UNIVERSITY OF TASMANIA · Oct 29, 2023
Trial Information
Current as of July 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This project aims to produce a solution for the rising incidence of dementia. This is particularly pertinent in Tasmania, with a rapidly ageing population. The investigators' will develop TapTalk, a new screening test that detects risk of Alzheimer's disease (AD) pathology. Accounting for 70% of all dementias, the brain pathology of AD progresses silently for more than 10 years before cognitive symptoms emerge (preclinical AD). It is possible to prevent 40% of dementia by modifying risk factors such as physical inactivity and smoking. However, the lack of a cost-effective screening tool mea...
Gender
ALL
Eligibility criteria
- • AIM 1 AND AIM 2 Eligibility criteria
- Inclusion Criteria:
- • Adults \>50 years old who are participants in the ISLAND Project and who have provided a blood sample and have normal cognition and no persistent (\>3 months) cognitive symptoms will be eligible.
- Exclusion Criteria:
- • Impaired cognition, defined by a validated cut-off score \>1.5 SD above the mean total errors adjusted for age and gender on the Paired Associates Learning sub-test of CANTAB.
- • AIM 3 Eligibility criteria Inclusion Criteria: \>3 months of persistent cognitive symptoms (patient- or family-reported) and \>50 years old.
- • Exclusion criteria: Acutely unwell, significant impairment of hand function, or known diagnosis of mild cognitive impairment (MCI) or dementia.
About University Of Tasmania
The University of Tasmania is a leading research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its expertise in various fields, including medicine, health sciences, and public health, to conduct rigorous and ethically sound research. Committed to fostering a culture of excellence, the University of Tasmania aims to translate research findings into practical applications that benefit the community and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hobart, Tasmania, Australia
Patients applied
Trial Officials
James Vickers, PhD
Study Director
University of Tasmania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported